With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines.
Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing its Sapu003 program and Deciparticle platform as key components of a wider industry shift toward scalable nanotechnology-driven drug delivery and AI-enhanced biomedical infrastructure. The company’s approach centers on leveraging platform technologies that may serve multiple therapeutic applications across oncology and rare disease markets rather than depending on a solitary drug candidate.
Oncotelic is among several companies, including CytoDyn Inc. (OTCQB: CYDY), Revolution Medicines Inc. (NASDAQ: RVMD), Moderna Inc. (NASDAQ: MRNA) and Sarepta Therapeutics Inc. (NASDAQ: SRPT), that are developing scalable biotechnology platforms designed to support multiple therapeutic programs across diverse disease areas. This trend reflects a strategic shift in the industry: instead of focusing on a single drug candidate, companies are building versatile platforms that can be applied to multiple targets, thereby reducing risk and potentially increasing returns on investment.
The drug-delivery market, encompassing novel formulations and delivery systems, is projected to reach $410 billion, driven by the demand for improved efficacy and patient compliance. Investors are taking note, as platform biotech models offer the promise of recurring revenue streams through licensing and partnerships. For instance, Oncotelic’s Deciparticle platform utilizes nanotechnology to enhance the delivery of chemotherapeutic agents, potentially reducing side effects and improving outcomes.
This approach is particularly relevant in oncology, where the cost of developing new drugs can exceed $1 billion, and the success rate from Phase I to approval is less than 10%. By repurposing existing drugs with better delivery mechanisms, companies can shorten development timelines and lower costs. Moreover, regulatory pathways for reformulated drugs may be more straightforward, as they often require less extensive clinical data compared to new chemical entities.
As the industry evolves, platform biotech models are likely to become more prevalent, offering a path to sustainable growth in an increasingly challenging environment. The convergence of AI and nanotechnology in drug delivery also opens new possibilities for personalized medicine, where treatments can be tailored to individual patient profiles. With the drug-delivery market heading toward $410 billion, companies that successfully commercialize such platforms stand to benefit significantly.
